Jefferies Adjusts Price Target on Moderna to $215
Jefferies has lowered its price target for Moderna, Inc. from $230 to $215.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Jefferies has lowered its price target for Moderna, Inc. from $230 to $215.
The non-small cell lung cancer market is shifting toward precision, biomarker-guided treatment sequencing. ESMO 2026 presented Phase III data showing savolitinib plus osimertinib improved survival in MET-altered EGFR-mutated NSCLC, divarasib outperformed approved KRAS G12C inhibitors, and TROP2-directed ADCs demonstrated durable gains. The 7MM NSCLC market is projected to double from USD 33 billion in 2025 to USD 67 billion by 2036, driven by expanded screening, biomarker-driven therapies, and label expansions into earlier-stage disease.
A $1,000 investment in an S&P 500 ETF at the peak of the dot-com bubble in March 2000 would have grown to $8,050 by November 2026, representing a 705% total return and 8% average annual return despite 13 years of stagnation. The article demonstrates that long-term wealth building doesn't require perfect market timing, but rather consistent investment through market cycles.
AstraZeneca has extended its 2021 master services agreement with Tempus AI through December 31, 2031, committing to $200 million in total fees.
Goldman Sachs and UBS project the S&P 500 will rise to 8,700-8,900 by 2027, supported by strong economic growth, attractive valuations following recent market corrections, and continued earnings growth despite expected slowdown. The U.S. economy expanded 3.4% in Q3 2026, and consumer sentiment improved, suggesting robust spending ahead. However, concerns remain over AI regulation, elevated inflation, and potential Fed hawkishness.
The global pharmaceutical market is valued at USD 1.88 trillion in 2026 and is projected to reach USD 3.20 trillion by 2035 at a CAGR of 6.10%. Growth is concentrated in obesity and oncology therapies, with U.S. pricing deals and Section 232 tariffs reshaping manufacturing. North America holds 42% of the market, while companies with strong positions in GLP-1 medicines and cancer therapies are growing significantly faster than the market.